29.55
-0.26 (-0.87%)
| Previous Close | 29.81 |
| Open | 29.48 |
| Volume | 668,796 |
| Avg. Volume (3M) | 1,706,254 |
| Market Cap | 4,781,278,720 |
| Price / Earnings (TTM) | 12.90 |
| Price / Earnings (Forward) | 20.20 |
| Price / Sales | 3.23 |
| Price / Book | 3.60 |
| 52 Weeks Range | |
| Earnings Date | 13 Feb 2025 - 17 Feb 2025 |
| Profit Margin | 22.15% |
| Operating Margin (TTM) | 27.70% |
| Diluted EPS (TTM) | 2.29 |
| Quarterly Revenue Growth (YOY) | -0.70% |
| Quarterly Earnings Growth (YOY) | 93.40% |
| Total Debt/Equity (MRQ) | 28.33% |
| Current Ratio (MRQ) | 3.45 |
| Operating Cash Flow (TTM) | 355.96 M |
| Levered Free Cash Flow (TTM) | 162.09 M |
| Return on Assets (TTM) | 8.98% |
| Return on Equity (TTM) | 29.23% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Alkermes plc | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.38 |
|
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 1.30% |
| % Held by Institutions | 113.81% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 43.00 (Cantor Fitzgerald, 45.52%) | Buy |
| Median | 37.00 (25.21%) | |
| Low | 26.00 (JP Morgan, -12.01%) | Hold |
| Average | 35.57 (20.37%) | |
| Total | 5 Buy, 2 Hold | |
| Avg. Price @ Call | 26.87 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Mizuho | 13 Nov 2024 | 40.00 (35.36%) | Buy | 29.24 |
| Stifel | 05 Nov 2024 | 36.00 (21.83%) | Buy | 28.37 |
| Cantor Fitzgerald | 25 Oct 2024 | 43.00 (45.52%) | Buy | 26.09 |
| 10 Oct 2024 | 48.00 (62.44%) | Buy | 27.37 | |
| Goldman Sachs | 25 Oct 2024 | 30.00 (1.52%) | Buy | 26.09 |
| HC Wainwright & Co. | 25 Oct 2024 | 37.00 (25.21%) | Hold | 26.09 |
| 14 Oct 2024 | 37.00 (25.21%) | Hold | 29.05 | |
| JP Morgan | 25 Oct 2024 | 26.00 (-12.01%) | Hold | 26.09 |
| Piper Sandler | 25 Oct 2024 | 37.00 (25.21%) | Buy | 26.09 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 02 Jan 2025 | Announcement | Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
| 25 Nov 2024 | Announcement | Alkermes to Participate in Upcoming Investor Conferences |
| 11 Nov 2024 | Announcement | Alkermes to Participate in Two Upcoming Investor Conferences |
| 07 Nov 2024 | Announcement | Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences |
| 24 Oct 2024 | Announcement | Alkermes plc Reports Third Quarter 2024 Financial Results |
| 17 Oct 2024 | Announcement | Alkermes to Report Third Quarter Financial Results on October 24, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |